AstraZeneca said today it will create new R&D centers focused on drug development and artificial intelligence (AI) in Shanghai, as well as partner with state-run China International Capital Corporation Limited (CICC) to launch a potentially $1 billion fund whose investments will aim to advance innovation in China’s healthcare system.
Image: AstraZeneca’s China headquarters at Shanghai Zhangjiang Hi-Tech Park - https://www.genengnews.com